aiwiki.page
English
Health / Diseases & Symptoms / neuromyelitis-optica-spectrum-disorder

Neuromyelitis Optica Spectrum Disorder

Neuromyelitis optica spectrum disorder is an autoimmune central nervous system disease causing attacks of optic nerve, spinal cord, and brain inflammation, often associated with aquaporin-4 antibodies.

39 keywords3 linked from5 not yet writtenWritten by AI
Autoimmune Disea…Central Nervous…Spinal CordBrainMultiple Scleros…DemyelinationPrevalenceIncidenceNeuromyeli…

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system characterized by inflammatory attacks affecting predominantly the optic nerves and spinal cord, but also specific regions of the brain. Its best-defined form is associated with immunoglobulin G antibodies against aquaporin-4, a water-channel protein concentrated on astrocytes. These antibodies distinguish the disease biologically from multiple sclerosis, with which it was historically confused.

Attacks can cause severe visual loss, limb weakness, sensory impairment, bladder dysfunction, or persistent vomiting and hiccups. Disability usually accumulates through incomplete recovery from individual attacks rather than through continuous deterioration between them. Consequently, treatment has two distinct purposes: limiting injury during an attack and preventing subsequent attacks. Identification of aquaporin-4 antibodies transformed diagnostic classification and enabled therapies directed at complement activation, antibody-producing cells, and interleukin-6 signaling.

The term spectrum disorder recognizes that the disease does not require simultaneous inflammation of both optic nerves and spinal cord. A characteristic first attack, together with a highly specific antibody result and exclusion of alternatives, may establish the diagnosis. Antibody-negative presentations require more restrictive criteria and remain biologically heterogeneous.

Historical development and disease boundaries

Descriptions of combined optic nerve and spinal cord disease appeared during the nineteenth century. In 1894, the French neurologist Eugène Devic and his student Fernand Gault assembled clinical observations that established the association as a recognizable syndrome. The resulting names, Devic disease and neuromyelitis optica, originally emphasized severe optic neuritis and transverse myelitis occurring together or close in time. These historical categories were based on symptoms and pathological findings rather than a known molecular cause.

For much of the twentieth century, neuromyelitis optica was variably regarded as a separate disease or an unusual form of multiple sclerosis. Both conditions could produce visual loss, spinal cord dysfunction, and demyelination, but several observations challenged their equivalence. Neuromyelitis optica often caused more destructive attacks, longer spinal cord lesions, and different inflammatory changes in tissue. Its distribution across populations also differed from that of multiple sclerosis. Before specific laboratory testing became available, however, the boundary between the conditions remained difficult to apply consistently.

A major turning point came in 2004, when Vanda Lennon and colleagues described a serum autoantibody, initially called NMO-IgG, that distinguished many affected patients from those with multiple sclerosis. In 2005, aquaporin-4 was identified as its target. The discovery established that the principal immune target was an astrocytic water channel rather than a component of myelin. Subsequent experimental and tissue studies showed that astrocyte injury could precede and drive damage to myelin and nerve fibers.

Diagnostic criteria revised in 2006 incorporated antibody testing and spinal magnetic resonance imaging. The concept of neuromyelitis optica spectrum disorders subsequently included restricted presentations, such as recurrent optic neuritis or recurrent extensive myelitis associated with aquaporin-4 antibodies. In 2015, the International Panel for NMO Diagnosis introduced a unified NMOSD framework with separate requirements for aquaporin-4-antibody-positive and antibody-negative disease.

Another important boundary emerged through recognition of myelin oligodendrocyte glycoprotein antibody-associated disease, usually abbreviated MOGAD. Some patients previously classified as antibody-negative NMOSD have antibodies against myelin oligodendrocyte glycoprotein and a different clinical course. MOGAD is now treated as a distinct disease rather than simply a subtype of NMOSD. The historical term neuromyelitis optica therefore remains useful descriptively, but it does not capture the full range or molecular distinctions of current classification.

Epidemiology and associated conditions

NMOSD is uncommon, although estimates vary substantially with population, case-finding methods, antibody assays, and diagnostic criteria. Published prevalence estimates generally range from below one to several cases per 100,000 people, with some population studies reporting values near or above 10 per 100,000. Annual incidence is usually measured in fractions of a case per 100,000 people. Older estimates are not directly comparable with modern studies because they often excluded isolated antibody-positive syndromes or included patients now classified as having MOGAD.

Aquaporin-4-antibody-positive disease has a pronounced female predominance, commonly around 8–9 women for every man. This sex difference is much less marked in several antibody-negative groups. Onset is most common in middle adulthood, often during the fourth or fifth decade, but the disease occurs in children and older adults as well. Age affects presentation and recovery: older-onset disease frequently involves substantial spinal cord disability, whereas childhood inflammatory syndromes require especially careful distinction from MOGAD and other disorders.

Population studies have documented NMOSD across the world. Compared with multiple sclerosis, it constitutes a larger share of inflammatory demyelinating disease in many Asian, African, and Latin American populations. Some studies report higher incidence or prevalence among people of African or Asian ancestry than among populations of European ancestry. These findings do not imply a simple ancestry-based cause. Genetic background, environmental exposures, referral patterns, access to antibody testing, and differences in survival and case ascertainment all affect observed rates.

Susceptibility is complex rather than following a straightforward inherited pattern. Familial cases occur, but most patients have no affected relative. Associations with particular human leukocyte antigen variants differ among populations, supporting a role for immune regulation rather than a single causative mutation. No infectious agent has been established as the universal cause, and the disease is not contagious.

Additional autoimmune disorders occur more often than expected by chance. Associations include systemic lupus erythematosus, Sjögren disease, autoimmune thyroid disease, and myasthenia gravis. Antinuclear and other systemic autoantibodies may also be present without a separate systemic diagnosis. Their presence does not by itself explain a characteristic aquaporin-4-associated neurological syndrome. Conversely, NMOSD can coexist with systemic autoimmunity, so the two diagnoses are not mutually exclusive.

Rare associations with cancer have been reported, including tumors expressing aquaporin-4. These observations support a paraneoplastic mechanism in a small minority of cases, not a general interpretation of NMOSD as a cancer-related disorder.

Aquaporin-4 autoimmunity and tissue injury

Aquaporin-4 is a membrane water channel expressed prominently by astrocytes, cells that support neuronal function, regulate the extracellular environment, and help maintain the blood–brain barrier. It is especially concentrated at astrocytic endfeet surrounding blood vessels and at interfaces between nervous tissue, blood, and cerebrospinal fluid. Its regional distribution helps explain the characteristic involvement of optic nerves, central spinal cord, and areas bordering the cerebral ventricles.

In aquaporin-4-antibody-positive NMOSD, the pathogenic antibody is predominantly of the IgG1 subclass. It recognizes extracellular portions of aquaporin-4 and can bind channel assemblies known as orthogonal arrays of particles. Much of the antibody is produced outside the central nervous system by cells of the B-cell lineage. Access to nervous tissue depends on local barrier properties and inflammatory conditions; circulating antibody alone does not fully explain where or when an attack occurs.

Antibody binding activates the complement system, a cascade of immune proteins capable of amplifying inflammation and damaging cell membranes. Complement activation generates inflammatory mediators and the terminal membrane attack complex. Neutrophils, eosinophils, macrophages, and other immune cells accumulate around affected vessels. Antibody-dependent cellular injury can contribute alongside complement-mediated damage. These processes cause astrocyte dysfunction and loss, followed by disruption of tissue support and injury to oligodendrocytes, myelin, and axons.

The histopathology differs from the usual pattern of multiple sclerosis. Characteristic active lesions show loss of aquaporin-4 and astrocytic proteins, perivascular immunoglobulin and complement deposition, and inflammatory infiltrates that may contain numerous granulocytes. Severe lesions can develop necrosis and cavitation. Demyelination is an important component of established injury, but the initiating target in antibody-positive NMOSD is an astrocyte rather than the myelin sheath itself.

Interleukin-6 contributes to several stages of this process. It supports survival of antibody-secreting plasmablasts, influences inflammatory lymphocyte responses, and can increase blood–brain barrier permeability. This provides a mechanistic basis for therapies that block its receptor. Similarly, the involvement of antibody-producing B-cell populations and terminal complement explains the effects of B-cell-depleting and complement-inhibiting drugs.

The biological basis of persistently aquaporin-4-antibody-negative NMOSD is less uniform. Some cases reflect assay limitations or antibody levels reduced by treatment; others represent distinct inflammatory diseases. The aquaporin-4 model therefore cannot automatically be applied to every patient meeting clinical criteria for seronegative NMOSD.

Clinical attacks and characteristic syndromes

Optic neuritis commonly causes visual loss developing over hours to days, often accompanied by pain on eye movement, impaired color vision, and visual field defects. NMOSD-associated optic neuritis may be severe, involve both eyes, or affect the posterior optic nerve and optic chiasm. Simultaneous bilateral disease is characteristic but not required. Recovery varies, and a single attack can leave substantial permanent visual impairment. Repeated attacks may affect the same eye or alternate between eyes.

Acute myelitis produces combinations of weakness, altered sensation, neuropathic pain, and bladder, bowel, or sexual dysfunction. A sensory level on the trunk may help localize spinal cord injury. Cervical lesions can affect all four limbs, while thoracic lesions predominantly affect the legs. High cervical or medullary involvement can compromise breathing. Painful tonic spasms—brief episodes of involuntary muscle contraction—may occur during recovery and are particularly associated with prior spinal cord attacks.

The characteristic imaging pattern is longitudinally extensive transverse myelitis, defined as a spinal cord lesion extending across at least three contiguous vertebral segments. Such lesions often occupy the central cord and may produce swelling during an acute attack. This pattern is diagnostically important but is neither universal in NMOSD nor specific to it. Short lesions can occur, especially early in an attack or after a longer lesion has partly resolved.

Area postrema syndrome consists of otherwise unexplained persistent hiccups, nausea, or vomiting associated with involvement of the dorsal medulla. The area postrema participates in emetic signaling and has specialized vascular properties that differ from much of the brain. Symptoms may precede optic neuritis or myelitis and can initially resemble gastrointestinal disease. Associated weight loss, fluid loss, or electrolyte abnormalities may result from prolonged vomiting rather than primary digestive pathology.

Other recognized presentations include acute brainstem syndromes causing double vision, swallowing difficulty, vertigo, or altered facial sensation. Diencephalic involvement can produce symptomatic narcolepsy or endocrine disturbances, sometimes associated with lesions around the hypothalamus. Cerebral attacks may cause focal neurological deficits, encephalopathy, or seizures, although these presentations are less characteristic than optic neuritis and myelitis.

Most aquaporin-4-positive patients have a relapsing course. Attacks can be separated by weeks, months, or years, and symptoms need not recur in the same anatomical location. Apparent worsening during infection, fever, or heat exposure can also represent temporary re-emergence of old deficits rather than a new inflammatory lesion. Distinguishing these events is important when assessing disease activity and treatment effects.

Diagnostic criteria, antibody assays, and imaging

The 2015 international criteria distinguish NMOSD with aquaporin-4 immunoglobulin G from NMOSD without detectable aquaporin-4 antibodies or with unknown antibody status. For antibody-positive disease, at least one of six core clinical characteristics is required, together with a reliable positive antibody result and exclusion of a better explanation. The six categories are optic neuritis, acute myelitis, area postrema syndrome, acute brainstem syndrome, a characteristic acute diencephalic syndrome, and a characteristic symptomatic cerebral syndrome.

Antibody-negative diagnosis is more restrictive. At least two core clinical characteristics are required, representing dissemination across different central nervous system regions. At least one must be optic neuritis, acute myelitis with a longitudinally extensive lesion, or area postrema syndrome. Additional syndrome-specific magnetic resonance imaging requirements apply. These safeguards reflect the greater risk of classifying unrelated diseases as NMOSD when the defining antibody is absent.

Serum is generally the preferred specimen for aquaporin-4 antibody testing. Cell-based assays display aquaporin-4 on the surface of laboratory cells and have the best-established combination of diagnostic sensitivity and specificity. Both live-cell and validated fixed-cell methods are used. Less specific methods can yield misleading low-positive results, especially when testing people with an atypical clinical presentation. A laboratory result therefore has to be interpreted alongside the clinical syndrome and imaging, rather than treated as a diagnosis in isolation.

A negative result does not completely exclude aquaporin-4-associated disease. Sampling after corticosteroids, plasma exchange, or other immunotherapy can reduce detectability, and assay performance varies. Repeat testing with an appropriate method can clarify selected clinically suspicious cases. Serum testing for MOG antibodies helps identify an important alternative, particularly in aquaporin-4-negative optic neuritis or myelitis. Testing cerebrospinal fluid for aquaporin-4 antibodies generally adds less diagnostic value than serum testing.

MRI evaluates the optic nerves, spinal cord, and brain. Suggestive findings include posterior optic pathway or chiasmal involvement, central longitudinally extensive spinal lesions, dorsal medullary lesions, and abnormalities adjacent to the third or fourth ventricles. Some patients have extensive hemispheric or corpus callosum lesions. Brain abnormalities do not exclude NMOSD, and an initially normal brain scan is not required.

Cerebrospinal fluid may show increased white cells and protein during an attack; neutrophils or eosinophils can occur. Persistent cerebrospinal-fluid-restricted oligoclonal bands, common in multiple sclerosis, are less frequent in NMOSD. Their presence does not absolutely exclude NMOSD, and their absence does not establish it. Diagnosis rests on the combined pattern of clinical events, antibody findings, imaging, and exclusion of competing causes.

Differential diagnosis and overlapping presentations

The most consequential differential diagnosis is multiple sclerosis because the diseases differ in biological mechanism, expected course, and response to treatment. Multiple sclerosis commonly produces characteristic periventricular and juxtacortical brain lesions, relatively short peripheral spinal cord lesions, and persistent cerebrospinal-fluid-restricted oligoclonal bands. NMOSD more often produces severe optic neuritis, central extensive myelitis, and area postrema syndrome. None of these features alone is absolute, but a compatible presentation with a reliable aquaporin-4 antibody result strongly supports NMOSD.

MOGAD can also cause optic neuritis, myelitis, and brainstem disease. Features favoring MOGAD include marked optic disc swelling, anterior optic nerve involvement, enhancement around the optic nerve sheath, and involvement of the conus medullaris. Acute disseminated encephalomyelitis, particularly in children, is another important MOGAD-associated presentation. Recovery and relapse patterns differ from those of aquaporin-4-positive NMOSD, although either disease can cause lasting disability. Low-positive MOG antibody results require careful interpretation because indiscriminate testing increases false-positive diagnoses.

Neurosarcoidosis can produce extensive spinal cord lesions, optic neuropathy, and meningeal inflammation. Persistent enhancement, certain patterns of subpial spinal cord enhancement, and systemic findings can help distinguish it. Malignancy, including lymphoma and infiltrating spinal tumors, can also resemble inflammatory disease. Progressively worsening symptoms without clear attacks, persistent mass-like abnormalities, or an atypical response to treatment may indicate an alternative process.

Infectious myelitis, spinal cord infarction, vascular malformations, and compressive spinal disease are additional mimics. A spinal dural arteriovenous fistula can produce a long cord lesion and gradually worsening leg dysfunction. Infarction often reaches maximal severity much faster than inflammatory myelitis. Vitamin B12 or copper deficiency can cause spinal cord syndromes, usually with a distribution and tempo different from an acute NMOSD attack. These distinctions require consideration of symptom timing, examination, imaging, and laboratory findings together.

Systemic autoimmune disease creates another diagnostic challenge. A person with lupus or Sjögren disease may have neurological complications from vascular injury, infection, medication effects, or a coexisting aquaporin-4-associated disorder. Attributing all neurological symptoms to the systemic diagnosis can obscure NMOSD. Conversely, a positive systemic autoantibody without the appropriate neurological and radiological pattern does not establish NMOSD.

The seronegative category is particularly vulnerable to misclassification. It includes patients who meet strict clinical criteria but lack a confirmed molecular marker. As antibody assays and disease classifications improve, some of these cases are reassigned. This uncertainty limits the interpretation of treatment studies that combine antibody-positive and antibody-negative participants without analyzing them separately.

Treatment of acute attacks

Acute attack treatment aims to suppress inflammation before irreversible astrocytic and axonal injury becomes extensive. Recovery is influenced by attack severity, anatomical location, prior damage, and the interval between symptom onset and treatment. Because disability often follows individual attacks, an episode of optic neuritis or myelitis represents a clinically important event even when previous attacks were widely separated.

High-dose intravenous corticosteroids are a standard initial treatment. Adult regimens commonly use methylprednisolone at 1 gram daily for three to five days, although protocols vary with clinical circumstances. Corticosteroids act broadly on inflammatory gene expression, immune-cell trafficking, and vascular permeability. An oral taper may follow, particularly while longer-term preventive treatment is being established. The evidence base includes accumulated clinical experience and observational studies rather than large placebo-controlled trials specific to NMOSD attacks.

Plasma exchange is a major treatment for severe attacks or attacks with insufficient improvement after corticosteroids. It separates and removes plasma, replacing it with an appropriate fluid, thereby reducing circulating antibodies, complement components, and other inflammatory mediators. A course often comprises approximately five to seven exchanges, although schedules differ. Immunoadsorption, which selectively removes immunoglobulins from plasma, is used in some centers as an alternative.

Observational studies associate earlier apheresis with better recovery, and severe attacks are sometimes treated with corticosteroids and early plasma exchange rather than a prolonged sequence of unsuccessful therapies. However, comparisons are affected by differences in attack severity, treatment timing, and referral patterns. A lack of immediate recovery does not necessarily mean that treatment has had no effect: neurological improvement can continue over weeks or months, while established tissue destruction may remain permanent.

Evidence for intravenous immunoglobulin as an acute NMOSD treatment is more limited than for corticosteroids and plasma exchange. Other rescue approaches have been reported in selected refractory cases, but their effects are difficult to establish from small, uncontrolled series. The use of a drug for long-term relapse prevention does not automatically establish it as an effective treatment for an attack already in progress.

Acute care also addresses complications of the lesion and its treatment. Severe cervical myelitis can require respiratory support; immobility can increase the risk of thrombosis and pressure injury. Urinary retention, severe pain, swallowing impairment, and autonomic dysfunction may require specific management. Infection can coexist with an attack or temporarily worsen old deficits, making clinical assessment and appropriate laboratory investigation important components of acute care.

Prevention of relapses and targeted therapies

Long-term therapy is directed at preventing new attacks rather than reversing established neurological injury. In aquaporin-4-positive NMOSD, the risk and potential severity of recurrence have supported preventive immunotherapy even after a first recognized attack. Historically, widely used treatments included azathioprine, mycophenolate mofetil, and rituximab, often with corticosteroids during the period before the preventive drug reached its full effect. Much of the initial evidence for these approaches came from retrospective cohorts.

Rituximab targets CD20 on B cells and indirectly reduces the cellular populations that sustain autoantibody responses. It does not directly eliminate all long-lived antibody-secreting plasma cells. Its effectiveness is supported by observational studies and a small randomized trial, although regulatory indications differ among countries. Other conventional immunosuppressive drugs remain in use because of clinical experience, availability, cost, and individual treatment circumstances.

Targeted monoclonal antibody therapies established a stronger randomized-trial evidence base. In the 2019 PREVENT trial, adjudicated relapses occurred in 3 of 96 participants receiving eculizumab and 20 of 47 receiving placebo. Eculizumab blocks complement protein C5, interrupting terminal complement activation. Most trial participants continued background immunosuppression, an important feature when interpreting the results. Eculizumab received United States approval in 2019 for adults with aquaporin-4-antibody-positive NMOSD.

Inebilizumab targets CD19, which is expressed across a broader range of B-lineage cells than CD20, including some antibody-secreting cells. In the 2019 N-MOmentum randomized controlled trial, attacks occurred in 21 of 174 participants assigned inebilizumab and 22 of 56 assigned placebo during the randomized period. The study population was predominantly aquaporin-4-antibody-positive. United States approval followed in 2020. Satralizumab, an interleukin-6 receptor blocker, also received United States approval in 2020, supported by the SAkuraSky and SAkuraStar trials as add-on treatment and monotherapy, respectively.

Ravulizumab is a longer-acting C5 inhibitor evaluated in the CHAMPION-NMOSD study. No adjudicated relapses occurred during its primary treatment period, but the study used an external comparator drawn from the PREVENT placebo group rather than a concurrent randomized placebo arm. It received United States approval for aquaporin-4-antibody-positive adult NMOSD in 2024. Approval populations and access differ between jurisdictions.

These results cannot establish a simple ranking among drugs because trial populations, background treatments, follow-up, and relapse definitions differed. Treatment evidence is also much less certain for persistently aquaporin-4-negative NMOSD. Several multiple sclerosis drugs, including interferon beta and fingolimod, are ineffective or have been associated with worsening in NMOSD, underscoring the clinical importance of accurate classification.

Safety, pregnancy, and long-term disability

Preventive therapies have different safety profiles because they interfere with different components of the immune system. Terminal complement inhibition substantially increases susceptibility to meningococcal disease. Vaccination and, in specified circumstances, antimicrobial prophylaxis form part of product-specific risk-management procedures, but vaccination does not eliminate the risk. Other infections caused by encapsulated bacteria are also relevant. These risks are mechanistically distinct from those associated with broad lymphocyte suppression.

B-cell-depleting treatments can cause infusion reactions, reduced immunoglobulin concentrations, and increased infection susceptibility. Hepatitis B reactivation is an established concern with B-cell-directed therapies. Interleukin-6 receptor blockade can affect liver enzymes and neutrophil counts and can suppress inflammatory markers that ordinarily help signal infection. Conventional immunosuppressants have additional hematological, hepatic, reproductive, and malignancy-related considerations. Long-term corticosteroid exposure can contribute to osteoporosis, diabetes, cataracts, and other complications. Clinical safety assessment therefore extends beyond whether attacks have stopped.

Pregnancy has particular importance because NMOSD predominantly affects women and can begin during reproductive years. Observational cohorts have found increased relapse activity in the postpartum period, especially in the first months after delivery. Disease activity during pregnancy varies, and treatment interruption can confound comparisons. The effects of individual preventive drugs on pregnancy and breastfeeding differ considerably; evidence often comes from registries and observational exposure data rather than randomized trials.

Residual disability reflects the sites and severity of previous attacks. Visual impairment, weakness, sensory loss, spasticity, neuropathic pain, bladder and bowel dysfunction, and fatigue can persist even when inflammatory activity is controlled. Painful tonic spasms and other movement-related symptoms may interfere with mobility and sleep. Anxiety and depression can add to the burden of neurological impairment without being direct measures of inflammatory activity.

Rehabilitation addresses functioning rather than immune activity. Its components can include physical and occupational therapy, visual rehabilitation, mobility aids, management of swallowing or communication difficulties, and approaches to bladder and bowel dysfunction. Functional goals depend on the pattern of injury: a person with preserved walking but profound visual loss has needs that differ from those of someone with paraplegia and normal vision.

Outcome measurement remains challenging. The Expanded Disability Status Scale, adopted from multiple sclerosis research, gives considerable weight to walking ability and does not fully represent visual function, pain, fatigue, or autonomic symptoms. Health-related quality of life and patient-reported measures therefore capture information that neurological examination and relapse counts can miss. A treatment that prevents new attacks may be highly effective biologically while leaving substantial pre-existing disability unchanged.

Prognosis and unresolved research questions

NMOSD prognosis has changed with reliable antibody testing, earlier recognition, and more effective relapse prevention. Historical series often described severe visual and motor disability and substantial mortality, but many predated modern treatment and included differently classified diseases. Such figures cannot be transferred directly to contemporary, treated aquaporin-4-positive populations. Outcomes also differ with access to specialist care, antibody assays, acute apheresis, and preventive drugs.

Unlike multiple sclerosis, aquaporin-4-positive NMOSD usually does not show a prominent secondary progressive phase independent of attacks. Most sustained disability is attack-related. Nevertheless, studies have identified retinal thinning, imaging abnormalities, and biochemical evidence of nervous-system injury outside overt attacks. Whether these findings represent continuing subclinical disease, delayed consequences of earlier lesions, or other processes remains under investigation. Their long-term clinical significance is not yet fully established.

Predicting the next attack remains difficult. Aquaporin-4 antibody concentrations may fluctuate, but serial titers do not reliably predict relapse in an individual and are not a sufficient standalone measure of treatment success. Serum glial fibrillary acidic protein, released during astrocytic injury, is a promising biomarker of disease activity. Neurofilament light chain reflects neuroaxonal injury but is not specific to NMOSD. Standardized assays, validated thresholds, and evidence that biomarker-guided decisions improve outcomes are still needed.

The duration of preventive treatment is another unresolved issue. Relapses have occurred after immunotherapy withdrawal even following prolonged remission. At the same time, continued treatment carries cumulative safety, practical, and financial burdens. Available evidence does not define a universally safe point for discontinuation, nor does it establish that disappearance of detectable aquaporin-4 antibodies means the disease has permanently resolved.

Persistently antibody-negative disease remains a major classification problem. Improved discovery of neural autoantibodies, more specific imaging patterns, and careful reassessment of mimics may divide this group into biologically coherent disorders. This is especially important for trials, because an intervention targeting aquaporin-4-related complement injury may not have the same effect in another inflammatory condition.

Research also addresses mechanisms that initiate loss of immune tolerance, factors governing antibody access to the central nervous system, and ways to repair established tissue injury. Comparative effectiveness studies are needed to evaluate treatment sequencing, switching, and long-term safety outside tightly controlled trials. Because targeted therapies are expensive and availability is uneven, international registries and studies in underrepresented populations are important for determining how trial efficacy translates into sustained prevention of disability.